Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Current Deferred Revenue (2017 - 2018)

Historic Current Deferred Revenue for UroGen Pharma (URGN) over the last 2 years, with Q2 2018 value amounting to $86000.0.

  • UroGen Pharma's Current Deferred Revenue fell 7234.73% to $86000.0 in Q2 2018 from the same period last year, while for Jun 2018 it was $86000.0, marking a year-over-year decrease of 7234.73%. This contributed to the annual value of $650000.0 for FY2017, which is N/A changed from last year.
  • Per UroGen Pharma's latest filing, its Current Deferred Revenue stood at $86000.0 for Q2 2018, which was down 7234.73% from $196000.0 recorded in Q1 2018.
  • UroGen Pharma's 5-year Current Deferred Revenue high stood at $650000.0 for Q4 2017, and its period low was $86000.0 during Q2 2018.